The somatotropic axis and aging: mechanisms and persistent questions about practical implications
- PMID: 19371777
- PMCID: PMC4207209
- DOI: 10.1016/j.exger.2009.04.001
The somatotropic axis and aging: mechanisms and persistent questions about practical implications
Abstract
Reduced somatotropic (GH/IGF-1) signaling delays aging and extends longevity in laboratory mice. However, it is unclear whether the physiological decrease of GH and IGF-1 levels with age represents a symptom of declining neuroendocrine function, a cause of age-related alterations in body composition and functionality or a protective mechanism against age-associated disease. Although available clinical evidence does not support the use of recombinant GH as an anti-aging therapy, many studies suggest the potential utility of GH and GH secretagogues in the treatment of sarcopenia and frailty.
References
-
- Bartke A. Is growth hormone deficiency a beneficial adaptation to aging? Evidence from experimental animals. Trends Endocrinol Metabol. 2003;14:340–344. - PubMed
-
- Bartke A, Peluso MR, Moretz N, Wright C, Bonkowski M, Winters TA, Shanahan MF, Kopchick JJ, Banz WJ. Effects of soy-derived diets on plasma and liver lipids, glucose tolerance, and longevity in normal, long-lived and short-lived mice. Horm Metab Res. 2004;36:550–558. - PubMed
-
- Besson A, Salemi S, Gallati S, Jenal A, Horn R, Mullis PS, Mullis PE. Reduced longevity in untreated patients with isolated growth hormone deficiency. J Clin Endocrinol Metab. 2003;88:3664–3667. - PubMed
-
- Blackman MR, Sorkin JD, Munzer T, Bellantoni MF, Busby-Whitehead J, Stevens TE, Jayme J, O’Connor KG, O’Connor KG, Christmas C, Tobin JD, Stewart KJ, Cottrell E, St Clair C, Pabst KM, Harman SM. Growth hormone and sex steroid administration in healthy aged women and men: A randomized controlled trial. JAMA. 2002;288:2282–2292. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
